Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Bristol-Myers Squibb (NY: BMY )

48.94 +0.70 (+1.44%)
Streaming Delayed Price Updated: 3:33 PM EDT, Sep 13, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 6,197,436
Open 48.25
Bid (Size) 48.93 (10)
Ask (Size) 48.94 (9)
Prev. Close 48.24
Today's Range 48.20 - 49.08
52wk Range 39.35 - 60.58
Shares Outstanding 2,222,113,553
Dividend Yield 4.66%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Time To Invest And Or Trade In Bio-Tech Stocks?
Biotechnology stocks and biotech exchange-traded funds ETFs once played a significant role in growth equity rallies, but today it seems like those days are in the past. Will an interest rate cut help... 
Via Talk Markets
Topics ETFs
Bristol Myers Squibb to Report Results for Third Quarter 2024 on October 31, 2024
From Bristol Myers Squibb
Via Business Wire

Performance

YTD
-7.25%
-7.25%
1 Month
-0.25%
-0.25%
3 Month
+17.97%
+17.97%
6 Month
-6.77%
-6.77%
1 Year
-17.96%
-17.96%

More News

Read More
Bristol Myers Squibb Announces Dividend
From Bristol Myers Squibb
Via Business Wire
Bernie Sanders Says If You're Poor In America You'll Live 10-15 Years Less: 'Anybody Else See A Problem With That?'
Via Benzinga
Market Whales and Their Recent Bets on BMY Options
Via Benzinga
Enliven Therapeutics' Leukemia Candidate Could Challenge Pfizer, AstraZeneca In Broader Target Market: Analyst
Via Benzinga
Bristol Myers Squibb to Present Data at ESMO Demonstrating Ongoing Leadership in Immuno-Oncology and Progression of Assets from Its Differentiated Research Platforms
From Bristol Myers Squibb
Via Business Wire
2 Unstoppable Dividend Growth Stocks You Can Buy Now With $100
Via The Motley Fool
FDA Battles Backlog of Drug Factory Inspections Since COVID-19
Via Benzinga
Exposures Product Safety
Bristol Myers Squibb Employees to Relay Nearly 3,000 Miles Cross-Country Aspiring to Raise Over $1 Million for the V Foundation for Cancer Research
From Bristol Myers Squibb
Via Business Wire
Despite Medicare Negotiations, Americans May Still Have To Pay More For Prescription Drugs
Via Benzinga
Topics Economy
Exposures Interest Rates
2 Reasons Bristol Myers Squibb Stock Could Be a Bargain, Down 34% From Its All-Time High
Via The Motley Fool
2 No-Brainer Large-Cap Stocks to Buy With $500 Right Now
Via The Motley Fool
Long-Term Follow-Up Data from Phase 3 Study of CAMZYOS® (mavacamten) Underscores Established Efficacy and Safety Profile in Patients with Symptomatic Obstructive Hypertrophic Cardiomyopathy (oHCM)
From Bristol Myers Squibb
Via Business Wire
Stock Market Rally Mixed; Dow Jones Hits High While Nvidia Tumbles On Earnings: Weekly Review
Via Investor's Business Daily
Topics Stocks
Exposures US Equities
Benzinga's 'Stock Whisper' Index: 5 Stocks Investors Secretly Monitor But Don't Talk About Yet
Via Benzinga
As Regulators Gear Up To Decide On Bristol Myers' Schizophrenia Treatment, Neurocrine Biosciences' Data Disappoints Investors
Via Benzinga
Kohl's Posts Upbeat Q2 Earnings, Joins Box, Waldencast, AeroVironment And Other Big Stocks Moving Higher On Wednesday
Via Benzinga
Neurocrine Bio Dives As Schizophrenia Trial Results Lags Peers
Via Investor's Business Daily
3 High-Yield Dividend Stocks With Payout Ratios Below 75%
Via The Motley Fool
2 Beaten-Down S&P 500 Dividend Stocks to Buy on the Dip and Hold Forever
Via The Motley Fool
Topics Stocks
Exposures US Equities
Regulators Expected To Approve Innovative Schizophrenia Treatment From Bristol Myers, Karuna
Via Benzinga
Bristol Myers Squibb to Participate in Upcoming Investor Conferences
From Bristol Myers Squibb
Via Business Wire
Bristol Myers Squibb to Present Data Across Cardiovascular Portfolio at the European Society of Cardiology Congress 2024
From Bristol Myers Squibb
Via Business Wire
Cancer Medicines From Merck, Bristol Myers And BeiGene In Question, As FDA Committee To Discuss Limiting PD-1 Drugs For Stomach Cancer
Via Benzinga
Exposures Product Safety
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.